SEQUENT Stock Overview
Sequent Scientific Limited operates animal health business worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Sequent Scientific Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹126.05 |
| 52 Week High | ₹155.50 |
| 52 Week Low | ₹70.60 |
| Beta | 0.51 |
| 1 Month Change | 8.29% |
| 3 Month Change | -6.56% |
| 1 Year Change | 70.68% |
| 3 Year Change | -57.49% |
| 5 Year Change | 81.50% |
| Change since IPO | -29.74% |
Recent News & Updates
Recent updates
Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)
Apr 05
Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet
Mar 10Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?
Jan 31How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?
Jan 17Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?
Jan 05What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?
Dec 24Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?
Dec 12
Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly
Nov 22Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)
Nov 10The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It
Oct 20How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance?
Oct 05Is Sequent Scientific Limited's (NSE:SEQUENT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Sep 04Do Sequent Scientific's (NSE:SEQUENT) Earnings Warrant Your Attention?
Aug 20Sequent Scientific Limited's (NSE:SEQUENT) Earnings Haven't Escaped The Attention Of Investors
Jul 30Does Sequent Scientific (NSE:SEQUENT) Have A Healthy Balance Sheet?
Jul 10Shareholder Returns
| SEQUENT | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.8% | -0.5% | 1.4% |
| 1Y | 70.7% | 55.3% | 46.1% |
Return vs Industry: SEQUENT exceeded the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: SEQUENT exceeded the Indian Market which returned 46.1% over the past year.
Price Volatility
| SEQUENT volatility | |
|---|---|
| SEQUENT Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: SEQUENT has not had significant price volatility in the past 3 months.
Volatility Over Time: SEQUENT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 1,301 | Rajaram Narayanan | www.sequent.in |
Sequent Scientific Limited operates animal health business worldwide. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that supports API, pharmaceutical, personal care, and nutraceutical organizations, as well as provides method validation, stability, and microbiology for APIs and finished products.
Sequent Scientific Limited Fundamentals Summary
| SEQUENT fundamental statistics | |
|---|---|
| Market cap | ₹31.33b |
| Earnings (TTM) | -₹1.29b |
| Revenue (TTM) | ₹13.71b |
2.3x
P/S Ratio-24.4x
P/E RatioIs SEQUENT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEQUENT income statement (TTM) | |
|---|---|
| Revenue | ₹13.71b |
| Cost of Revenue | ₹8.11b |
| Gross Profit | ₹5.59b |
| Other Expenses | ₹6.88b |
| Earnings | -₹1.29b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.17 |
| Gross Margin | 40.80% |
| Net Profit Margin | -9.38% |
| Debt/Equity Ratio | 67.5% |
How did SEQUENT perform over the long term?
See historical performance and comparison